Business Wire

  1. Argonne Leverages AI And Supercomputing To Revolutionize Cancer Research 4/22/2025

    Discovering new drugs to treat cancer and predicting how tumors will respond to them remain key challenges in the fight against the disease.

  2. Redwire Expands In-Space Drug Development Program, Launches New PIL-BOX Technology And Cancer-Detection Experiment 4/21/2025

    Redwire Corporation, a leader in space infrastructure for the next-generation space economy, announced today that it has launched a new drug development technology and a cancer-detection experiment to the International Space Station (ISS) as the company scales its in-space pharmaceutical drug development program based on the success of its PIL-BOX platform.

  3. Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors 4/21/2025

    Zai Lab Limited today announced that China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

  4. Aptar Announces Clinical Validation Study To Accelerate US FDA Approval Of SmartTrack™ In-Vitro-in-Silico Platform For Pressurized Metered-Dose Inhalers 4/16/2025

    AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a clinical study to validate its proprietary SmartTrack platform.

  5. Elix And PRISM BioLab Join Forces To Accelerate AI-Driven Drug Discovery For Challenging Protein-Protein Interaction Targets 4/15/2025

    Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter “Elix”), an AI drug discovery company with the mission of “Rethinking Drug Discovery”, today announced that it has entered into a drug discovery collaboration with PRISM BioLab, Co. Ltd. (CEO: Dai Takehara / HQ: Kanagawa, hereinafter "PRISM BioLab"), effective April 1, 2025.

  6. eGenesis And OrganOx Announce U.S. FDA Clearance Of IND Application For The Treatment Of Patients With Acute-On-Chronic Liver Failure 4/15/2025

    eGenesis, a biotechnology company developing human-compatible engineered organs to treat patients suffering from organ failure, and OrganOx Ltd., a leading organ medical technology company, today announced the U.S. Food & Drug Administration (FDA) has cleared the investigational new drug (IND) application for EGEN-5784, a human-compatible, genetically engineered porcine liver, used in combination with the OrganOx extracorporeal liver cross-circulation (ELC) system, for patients with acute-on-chronic liver failure (ACLF) suffering from decompensated liver function in the intensive care setting.

  7. Signios Bio Launches With AI-Driven Bioinformatics And Advanced Multiomics Platform To Power The Future Of Precision Medicine And Drug Discovery 4/10/2025

    Signios Biosciences ("Signios Bio"), a science-first biotechnology company at the forefront of multiomics and AI-powered bioinformatics, today announced its rebranding from its previous identity as the US based research division of MedGenome Inc.

  8. Tenpoint Therapeutics Ltd. Submits New Drug Application To U.S. FDA For BRIMOCHOL PF For The Treatment Of Presbyopia 4/8/2025

    Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BRIMOCHOL PF for the treatment of presbyopia, an age-related near-vision loss condition impacting approximately two billion people globally and 128 million people in the United States.

  9. CytoTronics Launches Neural Application For Pixel, Unleashing High-Throughput Screening Capability In Drug Discovery For Neurological Disease 4/8/2025

    CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, launched its Neural application for Pixel systems today. A pioneering innovation for neurodegenerative disease and neurotoxicity research, the application enables high-throughput screening for drug discovery at unprecedented scale.

  10. Plex Research Partners With Ginkgo Bioworks On Artificial Intelligence (AI)-Powered Drug Discovery To Identify Novel Disease Mechanisms And Pathways 4/3/2025

    Plex Research, a biotechnology company using autonomous artificial intelligence (AI) to aid in drug discovery, today announced that it is partnering with Ginkgo Datapoints, a service of Ginkgo Bioworks, to use the Plex AI Platform to deepen the understanding of compound treatment mechanisms of action, potentially revealing new therapeutic applications, based on a large perturbation response profiling dataset.